Eisai Co., Ltd. Overview
Pro stress-test →Eisai is a Japanese pharmaceutical company focused on neurology and oncology that discovers, develops, manufactures and markets prescription medicines, OTC drugs and generics. Key products include LEQEMBI for early-stage Alzheimer's disease, Lenvima for cancer treatment, and Dayvigo for insomnia.
Strategic Profile
Pro stress-test →The vast majority of Eisai's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies to expand its research, development, manufacturing, and marketing capabilities. The stock trades at a trailing P/E of 31.8x, above the 15.4x average for the Japanese pharmaceuticals industry.
Competitive Landscape
Pro stress-test →Eisai competes within the Drug Manufacturers—Specialty & Generic sector against peers like Takeda Pharmaceutical (market cap ¥7.8T). The company's focus on neurology and oncology puts it in competition with global pharmaceutical giants including Pfizer, Merck, and Bristol Myers Squibb. Eisai's differentiation centers on specialized therapeutic areas and licensing strategies.
Industry Context
Eisai Co., Ltd. operates in Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing.
Key facts
Founded: 1941 · Headquarters: Tokyo, Japan · Employees: 13,506 · Revenue: $5.06B · Market cap: $8.3B